Cipher Pharmaceuticals Inc
Research Cipher Pharmaceuticals Inc (CPH) on Bullrun: market cap CAD 358.35M, P/E 9.1. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerCPH
- ExchangeTO
- CountryCanada
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
- CurrencyCAD
- Market capCAD 358.35M
- P/E9.1
- Financial periodQ1 2026
- RevenueUSD 12.51M
- Net incomeUSD 6.16M
- Free cash flowUSD 3.96M
- Gross margin82.3%
Valuation Snapshot
latest market cap is CAD 358.35M; P/E is 9.1.
Peer valuation comparison
Latest P/E is 9.1x versus a Healthcare sector median of 24.46x (62.8% below).
Latest P/E is 9.1x versus a Canada median of 15.58x (41.6% below).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 50.45M | USD 27.33M | USD 29.53M | 80.1% | n/a | USD 7.49M | USD 5.51M | USD 126.24M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-23 | CAD 358.35M | 9.1 | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 CAD.
About Cipher Pharmaceuticals Inc
Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Actikerall, a topical solution for the treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead, and balding scalp; Vaniqa, a topical cream for the slowing of the growth of unwanted facial hair in women;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Cipher Pharmaceuticals Inc's market cap?
Cipher Pharmaceuticals Inc's market capitalization is CAD 358.35M.
What is Cipher Pharmaceuticals Inc's P/E ratio?
Cipher Pharmaceuticals Inc's price-to-earnings (P/E) ratio is 9.1.
What does Cipher Pharmaceuticals Inc do?
Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Actikerall, a topical solution for the treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead, and balding scalp; Vaniqa, a topical cream for the slowing of the growth of unwanted facial hair in women; Durela, an opioid analgesic for the management of moderate to moderately severe pain in.